GENMAB A/S DKK (GNMSF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Feb 17, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GNMSF SEC filings page.
GENMAB A/S DKK (GNMSF) reported $3.7B in revenue for fiscal year 2025, up 19.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Genmab grew revenue while margins narrowed, and its balance-sheet expansion introduced substantial debt without materially lifting cash generation.
In FY2025, revenue increased19.2% while operating cash flow increased only5.3% , revealing weaker cash conversion from incremental sales than the top line suggests. Net income fell15.0% , yet operating cash flow reached123.2% of net income, so reported earnings weakened more than cash generation and the two measures diverged.
R&D consumed
Total assets rose
Financial Health Signals
GENMAB A/S DKK does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
GENMAB A/S DKK scores 3.49, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $27.5B against total liabilities of $7.0B. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
GENMAB A/S DKK passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, GENMAB A/S DKK generates $1.23 in operating cash flow ($1.2B OCF vs $963.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
GENMAB A/S DKK earns $39.44 in operating income for every $1 of interest expense ($1.1B vs $27.0M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
GENMAB A/S DKK generated $3.7B in revenue in fiscal year 2025. This represents an increase of 19.2% from the prior year.
GENMAB A/S DKK reported $963.0M in net income in fiscal year 2025. This represents a decrease of 15.0% from the prior year.
GENMAB A/S DKK earned $15.37 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 12.3% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
GENMAB A/S DKK generated $1.1B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 4.5% from the prior year.
GENMAB A/S DKK held $1.7B in cash against $5.0B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
GENMAB A/S DKK's gross margin was 93.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.8 percentage points from the prior year.
GENMAB A/S DKK's operating margin was 28.6% in fiscal year 2025, reflecting core business profitability. This is down 2.5 percentage points from the prior year.
GENMAB A/S DKK's net profit margin was 25.9% in fiscal year 2025, showing the share of revenue converted to profit. This is down 10.4 percentage points from the prior year.
GENMAB A/S DKK's ROE was 16.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 5.6 percentage points from the prior year.
Capital Allocation
GENMAB A/S DKK invested $1.6B in research and development in fiscal year 2025. This represents an increase of 13.6% from the prior year.
GENMAB A/S DKK spent $430.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 23.2% from the prior year.
GENMAB A/S DKK invested $37.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 37.0% from the prior year.
GNMSF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F |
|---|---|---|---|
| Revenue | $3.7B+19.2% | $3.1B+30.6% | $2.4B |
| Cost of Revenue | $238.0M+66.4% | $143.0M+333.3% | $33.0M |
| Gross Profit | $3.5B+16.9% | $3.0B+26.3% | $2.4B |
| R&D Expenses | $1.6B+13.6% | $1.4B+27.7% | $1.1B |
| Operating Income | $1.1B+9.6% | $972.0M+25.9% | $772.0M |
| Interest Expense | $27.0Mn/m | $0n/m | $0 |
| Income Tax | $241.0M+24.9% | $193.0M+3.8% | $186.0M |
| Net Income | $963.0M-15.0% | $1.1B+79.6% | $631.0M |
| EPS (Basic) | $15.50-12.2% | $17.66+82.6% | $9.67 |
| EPS (Diluted) | $15.37-12.3% | $17.53+83.0% | $9.58 |
| Diluted Shares (Avg) | 63M-3.0% | 65M-1.9% | 66M |
Not reported in any period shown, so not listed: SG&A Expenses, EBITDA.
GNMSF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F |
|---|---|---|---|
| Total Assets | $12.9B+100.7% | $6.4B+22.6% | $5.2B |
| Current Assets | $2.9B-26.0% | $3.9B-20.6% | $4.9B |
| Cash & Equivalents | $1.7B+24.3% | $1.4B-37.4% | $2.2B |
| Inventory | $18.0M+100.0% | $9.0M+12.5% | $8.0M |
| Accounts Receivable | $1.1B+20.5% | $923.0M+25.9% | $733.0M |
| Goodwill | $355.0M0.0% | $355.0Mn/m | $0 |
| Total Liabilities | $7.0B+450.2% | $1.3B+134.3% | $545.0M |
| Current Liabilities | $1.4B+91.8% | $744.0M+102.2% | $368.0M |
| Non-Current Liabilities | $5.6B+950.5% | $533.0M+201.1% | $177.0M |
| Long-Term Debt | $5.0Bn/m | $0n/m | $0 |
| Total Equity | $5.8B+13.8% | $5.1B+9.6% | $4.7B |
| Retained Earnings | $4.1B+20.8% | $3.4B+23.9% | $2.7B |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
GNMSF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F |
|---|---|---|---|
| Operating Cash Flow | $1.2B+5.3% | $1.1B+5.1% | $1.1B |
| Capital Expenditures | $37.0M+37.0% | $27.0M-49.1% | $53.0M |
| Free Cash Flow | $1.1B+4.5% | $1.1B+8.0% | $1.0B |
| Investing Cash Flow | -$5.6Bn/m | -$1.4Bn/m | -$185.0M |
| Financing Cash Flow | $4.8Bn/m | -$566.0Mn/m | -$89.0M |
| Share Buybacks | $430.0M-23.2% | $560.0M+591.4% | $81.0M |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid.
GNMSF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F |
|---|---|---|---|
| Gross Margin | 93.6%-1.8pp | 95.4%-3.2pp | 98.6% |
| Operating Margin | 28.6%-2.5pp | 31.1%-1.2pp | 32.3% |
| Net Margin | 25.9%-10.4pp | 36.3%+9.9pp | 26.4% |
| Return on Equity | 16.5%-5.6pp | 22.1%+8.6pp | 13.5% |
| Return on Assets | 7.5%-10.2pp | 17.7%+5.6pp | 12.1% |
| Current Ratio | 2.02-3.2x | 5.24-8.1x | 13.35 |
| Debt-to-Equity | 0.86+0.9x | 0.000.0x | 0.00 |
| Liabilities-to-Equity | 1.20+1.0x | 0.25+0.1x | 0.12 |
| Asset Turnover | 0.29-0.2x | 0.490.0x | 0.46 |
| FCF Margin | 30.9%-4.3pp | 35.2%-7.4pp | 42.6% |
Where GENMAB A/S DKK Ranks
Frequently Asked Questions
What is GENMAB A/S DKK's annual revenue?
GENMAB A/S DKK (GNMSF) reported $3.7B in total revenue for fiscal year 2025. This represents a 19.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is GENMAB A/S DKK's revenue growing?
GENMAB A/S DKK (GNMSF) revenue grew by 19.2% year-over-year, from $3.1B to $3.7B in fiscal year 2025.
Is GENMAB A/S DKK profitable?
Yes, GENMAB A/S DKK (GNMSF) reported a net income of $963.0M in fiscal year 2025, with a net profit margin of 25.9%.
How much debt does GENMAB A/S DKK have?
As of fiscal year 2025, GENMAB A/S DKK (GNMSF) had $1.7B in cash and equivalents against $5.0B in long-term debt.
What is GENMAB A/S DKK's gross margin?
GENMAB A/S DKK (GNMSF) had a gross margin of 93.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is GENMAB A/S DKK's operating margin?
GENMAB A/S DKK (GNMSF) had an operating margin of 28.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is GENMAB A/S DKK's net profit margin?
GENMAB A/S DKK (GNMSF) had a net profit margin of 25.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is GENMAB A/S DKK's return on equity (ROE)?
GENMAB A/S DKK (GNMSF) has a return on equity of 16.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is GENMAB A/S DKK's free cash flow?
GENMAB A/S DKK (GNMSF) generated $1.1B in free cash flow during fiscal year 2025. This represents a 4.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is GENMAB A/S DKK's operating cash flow?
GENMAB A/S DKK (GNMSF) generated $1.2B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are GENMAB A/S DKK's total assets?
GENMAB A/S DKK (GNMSF) had $12.9B in total assets as of fiscal year 2025, including both current and long-term assets.
What are GENMAB A/S DKK's capital expenditures?
GENMAB A/S DKK (GNMSF) invested $37.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does GENMAB A/S DKK spend on research and development?
GENMAB A/S DKK (GNMSF) invested $1.6B in research and development during fiscal year 2025.
What is GENMAB A/S DKK's current ratio?
GENMAB A/S DKK (GNMSF) had a current ratio of 2.02 as of fiscal year 2025, which is generally considered healthy.
What is GENMAB A/S DKK's debt-to-equity ratio?
GENMAB A/S DKK (GNMSF) had a debt-to-equity ratio of 0.86 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is GENMAB A/S DKK's liabilities-to-equity ratio?
GENMAB A/S DKK (GNMSF) had a liabilities-to-equity ratio of 1.20 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is GENMAB A/S DKK's return on assets (ROA)?
GENMAB A/S DKK (GNMSF) had a return on assets of 7.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is GENMAB A/S DKK's P/E ratio?
GENMAB A/S DKK (GNMSF) trades at 28.6x earnings, its market capitalization divided by $963.0M net income, FY2025. The market capitalization is $27.5B as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is GENMAB A/S DKK's price-to-sales ratio?
GENMAB A/S DKK (GNMSF) trades at 7.4x sales, its market capitalization divided by $3.7B revenue, FY2025. The market capitalization is $27.5B as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is GENMAB A/S DKK's Altman Z-Score?
GENMAB A/S DKK (GNMSF) has an Altman Z-Score of 3.49, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is GENMAB A/S DKK's Piotroski F-Score?
GENMAB A/S DKK (GNMSF) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are GENMAB A/S DKK's earnings high quality?
GENMAB A/S DKK (GNMSF) has an earnings quality ratio of 1.23x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can GENMAB A/S DKK cover its interest payments?
GENMAB A/S DKK (GNMSF) has an interest coverage ratio of 39.44x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.